TRAFALGAR INTERNATIONAL, INC.

GCAN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2021 FY2020 FY2019 FY2018 FY2017
Revenue $12.6K $48.0K $7.1K $95.4K $209
Cost of Revenue $12.7K $48.1K $3.1K $109
Gross Profit $-25 $-46 $4.0K $86.9K $100
Gross Margin -0.2% -0.1% 56.1% 91.1% 47.8%
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-343.1K $-294.5K $-525.3K $-190.9K $-622.6K
Operating Margin -2,716.9% -612.9% -7,378.1% -200.2% -297,873.7%
Interest Expense $-4.6K
Pretax Income $-602.2K $-951.2K $-1.6M $-839.1K
Income Tax Expense
Net Income $-602.2K $-951.2K $-1.6M $-839.1K $-807.2K
Net Margin -4,768.2% -1,979.8% -23,154.4% -879.8% -386,224.4%
EPS (Basic) $0.00 $-0.01 $-0.05 $-0.03 $-0.03
EPS (Diluted) $0.00 $-0.01 $-0.05 $-0.03 $-0.03
Shares Outstanding (Basic) 489.5M 464.8M 39.3M 31.9M 0
Shares Outstanding (Diluted) 489.5M 464.8M 39.3M 31.9M 0
Dividends Per Share